ctDNA Testing in High-Risk Clear Cell RCC: Current Evidence and Clinical Utility
The most accurate statement is C: ctDNA positivity predicts worse DFS, but current assays are not reliable for treatment selection. While emerging evidence suggests ctDNA may have prognostic value in detecting molecular residual disease, the KEYNOTE-564 trial and current guidelines do not support using ctDNA status to guide adjuvant pembrolizumab decisions 1.
Why ctDNA Cannot Currently Guide Treatment Decisions
The 2025 EAU guidelines explicitly acknowledge "the lack of biomarkers for patient selection to avoid overtreatment" as a key limitation in adjuvant RCC therapy 1. Despite pembrolizumab now having a strong recommendation based on overall survival benefit (HR 0.62,95% CI 0.44-0.87; p=0.005), treatment selection remains based on clinicopathological risk stratification from KEYNOTE-564 criteria, not molecular markers 1.
Current Evidence on ctDNA in RCC
Prognostic potential exists but lacks clinical validation:
- Postoperative ctDNA detection may identify patients at increased recurrence risk 2
- Case reports demonstrate ctDNA can detect molecular residual disease before radiographic recurrence 3
- ctDNA positivity correlates with adverse pathological features and metastatic disease 4
Critical limitations preventing clinical implementation:
- Limited analytical sensitivity restricts broader applicability 2
- Methodological heterogeneity across assays prevents standardization 2
- No prospective validation in treatment selection for adjuvant therapy
- KEYNOTE-564 showed pembrolizumab benefit across broad patient subgroups regardless of molecular markers 5
Why Other Statements Are Incorrect
Statement A (Negative ctDNA excludes recurrence risk): Fundamentally false. Your patient has high-risk clear cell RCC by pathological criteria, which carries substantial recurrence risk regardless of ctDNA status. The 2025 EAU guidelines base adjuvant recommendations on clinicopathological features (pT stage, grade, nodal status, M1 NED) 1. A negative ctDNA test does not eliminate the 23-32% recurrence risk in high-risk patients that prompted the KEYNOTE-564 trial design 5.
Statement B (Pembrolizumab benefits only ctDNA-positive patients): Contradicted by trial evidence. KEYNOTE-564 demonstrated disease-free survival benefit (HR 0.63,95% CI 0.50-0.80) across broad subgroups without molecular stratification 5. The strong recommendation for adjuvant pembrolizumab applies to all patients meeting clinicopathological risk criteria, not molecular subsets 1.
Statement D (ctDNA has high sensitivity for recurrence): Directly contradicted by available evidence. Current ctDNA assays have "limited analytical sensitivity" that restricts clinical applicability 2. While tumor-informed approaches may detect early recurrence in selected cases 3, sensitivity is insufficient for routine surveillance or treatment decisions.
Clinical Implications for Your Patient
This 62-year-old man with high-risk clear cell RCC should receive adjuvant pembrolizumab based on clinicopathological criteria, not ctDNA status 1. The 2025 EAU guidelines issue a strong recommendation for adjuvant pembrolizumab in patients with:
- Intermediate-high risk (pT2 grade 4/sarcomatoid N0M0; or pT3 any grade N0M0)
- High risk (pT4 N0M0; or any pT with N+ M0)
- M1 NED after complete metastasectomy within 1 year 1
Treatment Framework
- Initiate within 12 weeks of nephrectomy 6
- Duration: 17 cycles of pembrolizumab 200mg every 3 weeks (approximately 1 year) 5
- Counsel regarding: Significant DFS and OS benefit versus 32% grade 3-5 adverse event rate 5
- Quality of life: No clinically meaningful deterioration in HRQoL scores at week 52 7
Common Pitfalls to Avoid
- Do not withhold pembrolizumab based on negative ctDNA—treatment decisions require clinicopathological risk assessment
- Do not use ctDNA for patient selection—no validated cutoffs or prospective evidence support this approach
- Do not delay treatment awaiting molecular testing—pembrolizumab should start within 12 weeks post-nephrectomy 6
Future Directions
While ctDNA shows promise for detecting molecular residual disease and may eventually refine risk stratification 3, 2, prospective validation demonstrating incremental clinical utility beyond established clinicopathological models is required before routine implementation 2. Current research focuses on integrative models combining genomic, tissue-based, immune, and circulating parameters, but none support routine clinical use 2.
Until such validation emerges, adjuvant treatment decisions must rely on the proven KEYNOTE-564 eligibility criteria that demonstrated mortality benefit 1.